A new antigenic site of poliovirus recognized by an intertypic cross-neutralizing monoclonal antibody

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• Poliovirus poses a significant global health threat, necessitating ongoing research into viral neutralization mechanisms.
• Monoclonal antibodies are crucial tools for understanding viral structure and developing antiviral strategies.

Purpose of the Study:

• To characterize a novel neutralization antigenic site on poliovirus.
• To investigate the molecular basis of neutralization resistance in poliovirus.

Main Methods:

• Immunization of BALB/c mice with poliovirus type 2 (PV2) to generate monoclonal antibodies (mAbs).
• Selection and characterization of neutralization-resistant poliovirus variants (PV2 and PV1).
• Nucleotide sequencing of viral RNA to identify mutations in resistant variants.

Main Results:

• A monoclonal antibody, mAb 7J6, was identified that neutralizes both PV2 and poliovirus type 1 (PV1).
• Mutations in specific loops of VP2 (residues 239-245) and VP3 (residues 195-207) were found in neutralization-resistant variants.
• These findings provide the first evidence that these VP2 and VP3 loops constitute a neutralization antigenic site (N-Ag).
• This newly identified N-Ag on PV2 induced intertypic cross-neutralizing antibodies.

Conclusions:

• The study elucidates a novel neutralization antigenic site on poliovirus involving specific VP2 and VP3 loops.
• This site is critical for antibody recognition and neutralization.
• The induction of cross-neutralizing antibodies suggests potential for broader antiviral strategies.